Fierce Biotech

Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential

Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led ...